These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 18052043)

  • 21. Novel immunotoxin: a fusion protein consisting of gelonin and an acetylcholine receptor fragment as a potential immunotherapeutic agent for the treatment of Myasthenia gravis.
    Hossann M; Li Z; Shi Y; Kreilinger U; Büttner J; Vogel PD; Yuan J; Wise JG; Trommer WE
    Protein Expr Purif; 2006 Mar; 46(1):73-84. PubMed ID: 16230023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autoimmune diseases involving nicotinic receptors.
    Lindstrom J
    J Neurobiol; 2002 Dec; 53(4):656-65. PubMed ID: 12436428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three-dimensional location of the main immunogenic region of the acetylcholine receptor.
    Beroukhim R; Unwin N
    Neuron; 1995 Aug; 15(2):323-31. PubMed ID: 7544140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipopolysaccharide bound structures of the active fragments of fowlicidin-1, a cathelicidin family of antimicrobial and antiendotoxic peptide from chicken, determined by transferred nuclear Overhauser effect spectroscopy.
    Bhunia A; Mohanram H; Bhattacharjya S
    Biopolymers; 2009; 92(1):9-22. PubMed ID: 18844294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antigen-specific apheresis of human anti-acetylcholine receptor autoantibodies from myasthenia gravis patients' sera using Escherichia coli-expressed receptor domains.
    Zisimopoulou P; Lagoumintzis G; Poulas K; Tzartos SJ
    J Neuroimmunol; 2008 Aug; 200(1-2):133-41. PubMed ID: 18603305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NMR evidence of charge-dependent interaction between various PND V3 and CCR5 N-terminal peptides.
    Galanakis PA; Kandias NG; Rizos AK; Morikis D; Krambovitis E; Spyroulias GA
    Biopolymers; 2009; 92(2):94-109. PubMed ID: 19117029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural insights into the molecular mechanisms of myasthenia gravis and their therapeutic implications.
    Noridomi K; Watanabe G; Hansen MN; Han GW; Chen L
    Elife; 2017 Apr; 6():. PubMed ID: 28440223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complementary strategies to elucidate T helper cell epitopes in myasthenia gravis.
    Jung C; Stoeckle C; Wiesmüller KH; Laub R; Emmrich F; Jung G; Melms A
    J Neuroimmunol; 2008 Sep; 201-202():41-9. PubMed ID: 18649950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antibodies in myasthenia gravis].
    Eymard B
    Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional organization and conformational dynamics of the nicotinic receptor: a plausible structural interpretation of myasthenic mutations.
    Taly A; Changeux JP
    Ann N Y Acad Sci; 2008; 1132():42-52. PubMed ID: 18567852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.
    Yi HJ; Chae CS; So JS; Tzartos SJ; Souroujon MC; Fuchs S; Im SH
    Mol Immunol; 2008 Nov; 46(1):192-201. PubMed ID: 18799218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proliferative responses to acetylcholine receptor peptides in myasthenia gravis.
    Berrih-Aknin S; Cohen-Kaminsky S; Neumann D; Bach JF; Fuchs S
    Ann N Y Acad Sci; 1988; 540():504-5. PubMed ID: 2462824
    [No Abstract]   [Full Text] [Related]  

  • 33. Regulation of experimental autoimmune myasthenia gravis by synthetic peptides of the acetylcholine receptor.
    Souroujon MC; Carmon S; Fuchs S
    Ann N Y Acad Sci; 1993 Jun; 681():332-4. PubMed ID: 8357185
    [No Abstract]   [Full Text] [Related]  

  • 34. Antigenic structure of the muscle nicotinic acetylcholine receptor.
    Tzartos SJ; Cung MT; Mamalaki A; Marraud M; Papanastasiou D; Sakarellos C; Sakarellos-Daitsiotis M; Tsantili P
    Ann Med Interne (Paris); 1996; 147(6):442-6. PubMed ID: 9092347
    [No Abstract]   [Full Text] [Related]  

  • 35. Structure of the third intracellular loop of the vasopressin V2 receptor and conformational changes upon binding to gC1qR.
    Bellot G; Granier S; Bourguet W; Seyer R; Rahmeh R; Mouillac B; Pascal R; Mendre C; Déméné H
    J Mol Biol; 2009 May; 388(3):491-507. PubMed ID: 19285506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera.
    Tzartos SJ; Bitzopoulou K; Gavra I; Kordas G; Jacobson L; Kostelidou K; Lagoumintzis G; Lazos O; Poulas K; Sideris S; Sotiriadis A; Trakas N; Zisimopoulou P
    Ann N Y Acad Sci; 2008; 1132():291-9. PubMed ID: 18567880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An engineered tryptophan zipper-type peptide as a molecular recognition scaffold.
    Cheng Z; Campbell RE
    J Pept Sci; 2009 Aug; 15(8):523-32. PubMed ID: 19551843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis.
    Fuchs S; Feferman T; Meidler R; Margalit R; Sicsic C; Wang N; Zhu KY; Brenner T; Laub O; Souroujon MC
    J Neuroimmunol; 2008 Feb; 194(1-2):89-96. PubMed ID: 18178258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Familial occurrence of autoimmune myasthenia gravis with different antibody specificity.
    Lavrnic D; Nikolic A; De Baets M; Verschuuren J; Verduyn W; Losen M; Stojanovic V; Stevic Z; Hajdukovic Lj; Apostolski S
    Neurology; 2008 May; 70(21):2011-3. PubMed ID: 18490624
    [No Abstract]   [Full Text] [Related]  

  • 40. Loop 3 of short neurotoxin II is an additional interaction site with membrane-bound nicotinic acetylcholine receptor as detected by solid-state NMR spectroscopy.
    Krabben L; van Rossum BJ; Jehle S; Bocharov E; Lyukmanova EN; Schulga AA; Arseniev A; Hucho F; Oschkinat H
    J Mol Biol; 2009 Jul; 390(4):662-71. PubMed ID: 19447114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.